[1] HE Y,LONG W,LIU Q. Targeting super-enhancers as a therapeutic strategy for cancer treatment[J].Front Pharmacol, 2019, 10: 361.
[2] FURLONG E E M,LEVINE M. Developmental enhancers and chromosome topology[J].Science, 2018, 361(6409):1341-1345.
[3] HU Z,TEE W W. Enhancers and chromatin structures: regulatory hubs in gene expression and diseases[J].Biosci Rep, 2017, 37(2):BSR20160183.
[4] WHYTE W A,ORLANDO D A,HNISZ D,et al.Master transcription factors and mediator establish super-enhancers at key cell identity genes[J].Cell, 2013, 153(2):307-319.
[5] RI K,KIM C,PAK C,et al.The KLF6 super enhancer modulates cell proliferation via MiR-1301 in human hepatoma cells[J].Microrna, 2020, 9(1):64-69.
[6] JIANG Y Y,LIN D C,MAYAKONDA A, et al.Targeting super-enhancer-associated oncogenes in oesophageal squamous cell carcinoma[J].Gut, 2017, 66(8):1358-1368.
[7] OTT C J,FEDERATION A J,SCHWARTZ L S,et al.Enhancer architecture and essential core regulatory circuitry of chronic lymphocytic leukemia[J].Cancer Cell, 2018, 34(6):982-995.e7.
[8] LIU X,ZHANG Y,CHEN Y,et al.In situ capture of chromatin interactions by biotinylated dCas9[J].Cell, 2017, 170(5):1028-1043.e19.
[9] LAI B,LEE J E,JANG Y,et al.MLL3/MLL4 are required for CBP/p300 binding on enhancers and super-enhancer formation in brown adipogenesis[J].Nucleic Acids Res, 2017, 45(11):6388-6403.
[10] LIN R L,HUANG M,SHI X,et al.Super-enhancer-associated MEIS1 promotes transcriptional dysregulation in Ewing sarcoma in co-operation with EWS-FLI1[J].Nucleic Acids Res, 2019, 47(3):1255-1267.
[11] MARATT J K,SAINI S D. Colorectal cancer screening in the 21st century: where do we go from here? [J].Am J Manag Care, 2015, 21(7):e447-449.
[12] DE MOOR J S,COHEN R A,SHAPIRO J A,et al.Colorectal cancer screening in the United States: trends from 2008 to 2015 and variation by health insurance coverage[J].Prev Med, 2018, 112: 199-206.
[13] MIGOWSKI A,STEIN A T,FERREIRA C B T,et al.Guidelines for early detection of breast cancer in Brazil. I- Development methods[J].Cad Saude Publica, 2018, 34(6):e00116317.
[14] LEE M W,KIM G H,JEON H K,et al.Clinical application of circulating tumor cells in gastric cancer[J].Gut Liver, 2019, 13(4):394-401.
[15] ?IMON M,POP B,TOMA I L,et al.The use of EBUS-TBNA and ROSE in the diagnosis of lung cancer[J].Rom J Morphol Embryol, 2017, 58(1):79-87.
[16] BALDAUF M C,ORTH M F,DALLMAYER M,et al.Robust diagnosis of Ewing sarcoma by immunohistochemical detection of super-enhancer-driven EWSR1-ETS targets[J].Oncotarget, 2018, 9(2):1587-1601.
[17] LIU J,DUAN Z,GUO W,et al.Targeting the BRD4/FOXO3a/CDK6 axis sensitizes AKT inhibition in luminal breast cancer[J].Nat Commun, 2018, 9(1):5200.
[18] WONG M,SUN Y,XI Z,et al.JMJD6 is a tumorigenic factor and therapeutic target in neuroblastoma[J].Nat Commun, 2019, 10(1):3319.
[19] XING R,ZHOU Y,YU J,et al.Whole-genome sequencing reveals novel tandem-duplication hotspots and a prognostic mutational signature in gastric cancer[J].Nat Commun, 2019, 10(1):2037.
[20] 周晓明,毛幸,吴小涛. Yes相关蛋白在肿瘤中作用的研究进展[J].现代医学, 2016, 44(4):561-564.
[21] CHEN Y,XU L,MAYAKONDA A,et al.Bromodomain and extraterminal proteins foster the core transcriptional regulatory
programs and confer vulnerability in liposarcoma[J].Nat Commun, 2019, 10(1):1353.
[22] GAO H,CHEN X,CAI Q,et al.Increased KIF4A expression is a potential prognostic factor in prostate cancer[J].Oncol Lett, 2018, 15(5):7941-7947.
[23] CASLINI C, HONG S, BAN Y J,et al.HDAC7 regulates histone 3 lysine 27 acetylation and transcriptional activity at super-enhancer-associated genes in breast cancer stem cells[J].Oncogene, 2019, 38(39):6599-6614.
[24] SIN-CHAN P, MUMAL I, SUWAL T,et al.A C19MC-LIN28A-MYCN oncogenic circuit driven by hijacked super-enhancers is a distinct therapeutic vulnerability in ETMRs: a lethal brain tumor[J].Cancer Cell, 2019, 36(1):51-67.e7 |
